Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PRDS

Pardes Biosciences (PRDS)

Pardes Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRDS
DateTimeSourceHeadlineSymbolCompany
11/09/202322:00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:PRDSPardes Biosciences Inc
01/09/202307:17Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:PRDSPardes Biosciences Inc
01/09/202304:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRDSPardes Biosciences Inc
01/09/202304:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRDSPardes Biosciences Inc
31/08/202323:06Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PRDSPardes Biosciences Inc
31/08/202323:03Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRDSPardes Biosciences Inc
31/08/202323:01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRDSPardes Biosciences Inc
31/08/202322:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRDSPardes Biosciences Inc
31/08/202322:53Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202322:34Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202322:30Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202322:15GlobeNewswire Inc.Pardes Biosciences Announces Closing of Tender OfferNASDAQ:PRDSPardes Biosciences Inc
29/08/202302:11Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
29/08/202302:08Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
29/08/202301:52Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
29/08/202301:33Business WireMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesNASDAQ:PRDSPardes Biosciences Inc
18/08/202307:43Business WireMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesNASDAQ:PRDSPardes Biosciences Inc
18/08/202307:11Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
18/08/202307:09Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
18/08/202306:59Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
05/08/202306:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRDSPardes Biosciences Inc
05/08/202306:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRDSPardes Biosciences Inc
29/07/202307:08Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:PRDSPardes Biosciences Inc
29/07/202307:04Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:PRDSPardes Biosciences Inc
29/07/202307:01Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:PRDSPardes Biosciences Inc
17/07/202321:58Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:PRDSPardes Biosciences Inc
17/07/202321:55Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:PRDSPardes Biosciences Inc
17/07/202321:11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:PRDSPardes Biosciences Inc
17/07/202321:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRDSPardes Biosciences Inc
17/07/202321:00GlobeNewswire Inc.Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsNASDAQ:PRDSPardes Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:PRDS